ASH 2022 Conference Coverage
ASH 2022: Navitoclax and Ruxolitinib in JAKi-Naïve Patients With MF Mediates Responses Suggestive of Disease Modification in the Phase 2 REFINE Study
By
ASH 2022 Conference Coverage
FEATURING
Francesco Passamonti
By
ASH 2022 Conference Coverage
FEATURING
Francesco Passamonti
Login to view comments.
Click here to Login
